Trial Profile
An investigator initiated Phase I trial of alectinib in pediatric patients with refractory malignant solid tumors or malignant lymphoma(NCCH1708)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Acronyms PANDA
- 04 Feb 2020 Planned number of patients changed from 24 to 12.
- 21 Jun 2018 New trial record